Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

$28.59 +0.86 (+3.10%)

As of 05/8/2026

LKFT vs. QGEN, KYMR, ACLX, MIRM, and PTGX

Should you be buying Lakefront Biotherapeutics American Depositary Shares stock or one of its competitors? The main competitors of Lakefront Biotherapeutics American Depositary Shares include Qiagen (QGEN), Kymera Therapeutics (KYMR), Arcellx (ACLX), Mirum Pharmaceuticals (MIRM), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Lakefront Biotherapeutics American Depositary Shares compare to Qiagen?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $36.50, suggesting a potential upside of 27.67%. Qiagen has a consensus target price of $46.38, suggesting a potential upside of 40.35%. Given Qiagen's stronger consensus rating and higher probable upside, analysts plainly believe Qiagen is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Qiagen has a net margin of 19.16% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. Qiagen's return on equity of 14.09% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Qiagen	19.16%	14.09%	8.26%

In the previous week, Qiagen had 9 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 17 mentions for Qiagen and 8 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.79 beat Qiagen's score of 0.12 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Qiagen has higher revenue and earnings than Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.50	$363.05M	-$1.57	N/A
Qiagen	$2.09B	3.26	$424.88M	$1.91	17.30

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Qiagen beats Lakefront Biotherapeutics American Depositary Shares on 15 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Kymera Therapeutics?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $36.50, suggesting a potential upside of 27.67%. Kymera Therapeutics has a consensus target price of $118.10, suggesting a potential upside of 37.19%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.50	$363.05M	-$1.57	N/A
Kymera Therapeutics	$39.21M	180.59	-$311.35M	-$3.57	N/A

In the previous week, Kymera Therapeutics had 24 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 32 mentions for Kymera Therapeutics and 8 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.79 beat Kymera Therapeutics' score of 0.45 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Lakefront Biotherapeutics American Depositary Shares beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Arcellx?

Arcellx (NASDAQ:ACLX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Arcellx presently has a consensus target price of $111.87, suggesting a potential downside of 2.78%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $36.50, suggesting a potential upside of 27.67%. Given Lakefront Biotherapeutics American Depositary Shares' stronger consensus rating and higher possible upside, analysts clearly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.50	$363.05M	-$1.57	N/A

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 5 more articles in the media than Arcellx. MarketBeat recorded 8 mentions for Lakefront Biotherapeutics American Depositary Shares and 3 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.79 indicating that Arcellx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcellx	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Arcellx's net margin of -1,027.26%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcellx	-1,027.26%	-55.42%	-36.24%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Arcellx has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.

96.0% of Arcellx shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 8.4% of Arcellx shares are owned by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Lakefront Biotherapeutics American Depositary Shares beats Arcellx on 10 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 14.4% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Mirum Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.53	-$23.36M	-$13.61	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.50	$363.05M	-$1.57	N/A

Mirum Pharmaceuticals presently has a consensus target price of $136.42, suggesting a potential upside of 27.30%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $36.50, suggesting a potential upside of 27.67%. Given Lakefront Biotherapeutics American Depositary Shares' higher possible upside, analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14

In the previous week, Mirum Pharmaceuticals had 32 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 40 mentions for Mirum Pharmaceuticals and 8 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.79 beat Mirum Pharmaceuticals' score of 0.29 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	10 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-10.84%	-3.97%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.

Summary

Lakefront Biotherapeutics American Depositary Shares beats Mirum Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	138.85	-$130.15M	-$1.81	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.50	$363.05M	-$1.57	N/A

Protagonist Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.

In the previous week, Protagonist Therapeutics had 9 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 17 mentions for Protagonist Therapeutics and 8 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.79 beat Protagonist Therapeutics' score of 0.62 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 4.9% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Protagonist Therapeutics presently has a consensus target price of $113.69, suggesting a potential upside of 14.42%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $36.50, suggesting a potential upside of 27.67%. Given Lakefront Biotherapeutics American Depositary Shares' higher possible upside, analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14

Summary

Lakefront Biotherapeutics American Depositary Shares beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Lakefront Biotherapeutics American Depositary Shares News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LKFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LKFT vs. The Competition

Export

Metric	Lakefront Biotherapeutics American Depositary Shares	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.88B	$3.39B	$6.24B	$12.32B
Dividend Yield	N/A	2.25%	2.78%	5.22%
P/E Ratio	-18.21	15.62	21.19	25.42
Price / Sales	1.50	318.63	543.89	84.65
Price / Cash	38.19	122.48	43.07	53.89
Price / Book	0.49	7.32	9.97	6.83
Net Income	$363.05M	$24.23M	$3.55B	$333.46M
7 Day Performance	2.11%	2.21%	3.50%	3.08%
1 Month Performance	0.67%	5.78%	4.89%	7.52%
1 Year Performance	12.91%	78.95%	41.93%	41.50%

Lakefront Biotherapeutics American Depositary Shares Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LKFT Lakefront Biotherapeutics American Depositary Shares	2.9782 of 5 stars	$28.59 +3.1%	$36.50 +27.7%	+9.5%	$1.88B	$1.26B	N/A	1,310	News Coverage Earnings Report Gap Up
QGEN Qiagen	4.5195 of 5 stars	$33.91 -0.1%	$47.09 +38.9%	-25.0%	$6.99B	$2.09B	16.82	5,654	News Coverage Earnings Report Analyst Forecast
KYMR Kymera Therapeutics	2.9436 of 5 stars	$82.87 -0.9%	$118.70 +43.2%	+186.3%	$6.86B	$39.21M	N/A	170	Analyst Forecast Analyst Revision
ACLX Arcellx	2.0952 of 5 stars	$115.07 flat	$111.87 -2.8%	+99.2%	$6.73B	$22.29M	N/A	80	High Trading Volume
MIRM Mirum Pharmaceuticals	2.4687 of 5 stars	$108.69 +2.7%	$125.25 +15.2%	+142.1%	$6.61B	$521.31M	N/A	140	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LKFT) was last updated on 5/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. QGEN, KYMR, ACLX, MIRM, and PTGX

How does Lakefront Biotherapeutics American Depositary Shares compare to Qiagen?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Kymera Therapeutics?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Arcellx?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. QGEN, KYMR, ACLX, MIRM, and PTGX

How does Lakefront Biotherapeutics American Depositary Shares compare to Qiagen?

Do analysts recommend LKFT or QGEN?

Which has more volatility and risk, LKFT or QGEN?

Is LKFT or QGEN more profitable?

Does the media favor LKFT or QGEN?

Which has better earnings and valuation, LKFT or QGEN?

Do institutionals & insiders have more ownership in LKFT or QGEN?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Kymera Therapeutics?

Do analysts recommend LKFT or KYMR?

Which has better earnings and valuation, LKFT or KYMR?

Does the media favor LKFT or KYMR?

Is LKFT or KYMR more profitable?

Which has more volatility and risk, LKFT or KYMR?

Do institutionals & insiders have more ownership in LKFT or KYMR?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Arcellx?

Do analysts rate ACLX or LKFT?

Which has stronger valuation and earnings, ACLX or LKFT?

Does the media prefer ACLX or LKFT?

Is ACLX or LKFT more profitable?

Which has more risk & volatility, ACLX or LKFT?

Do insiders and institutionals hold more shares of ACLX or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Mirum Pharmaceuticals?

Do institutionals and insiders hold more shares of MIRM or LKFT?

Which has higher valuation & earnings, MIRM or LKFT?

Do analysts rate MIRM or LKFT?

Does the media prefer MIRM or LKFT?

Is MIRM or LKFT more profitable?

Which has more risk and volatility, MIRM or LKFT?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Which has higher valuation & earnings, PTGX or LKFT?

Which has more risk and volatility, PTGX or LKFT?

Does the media prefer PTGX or LKFT?

Do institutionals and insiders hold more shares of PTGX or LKFT?

Is PTGX or LKFT more profitable?

Do analysts rate PTGX or LKFT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools